How does mazdutide work?
Mazdutide is a once-a-week drug that switches on two receptors, GLP-1 and glucagon. It is based on oxyntomodulin, a natural gut hormone that acts on both. This site's profile says its half-life is about 5 to 7 days. Its molecular weight is about 4,800 daltons. Other names on the profile are IBI362 and LY3305677. A study in 731 Chinese adults with type 2 diabetes found both mazdutide doses beat dulaglutide 1.5 milligrams on long-term blood sugar (HbA1c), with 3.8 to 5.8 percentage points more weight loss at 28 weeks. GLORY-1 included 610 Chinese adults. At week 32, average weight change was down 10.1% at 4 milligrams and down 12.6% at 6 milligrams, versus up 0.5% on a dummy shot. It was approved in China in June 2025 for obesity and in September 2025 for type 2 diabetes, the first drug of this two-hormone type approved anywhere. It is not FDA approved. This FAQ does not invent a dose. Full record at /compounds/mazdutide.
Studies in people from the compound pages this answer belongs to
- Mazdutide
- Once-weekly mazdutide in Chinese adults with obesity or overweight (GLORY-1) 2025 PMID 40421736
- Mazdutide versus dulaglutide in Chinese adults with type 2 diabetes 2026 PMID 41407860
- Treatment With 9-mg Mazdutide for Weight Reduction in Chinese Adults With Obesity: The GLORY-2 Randomized Clinical Trial 2026 PMID 42251595
Educational use only. This database summarizes published research and is not medical advice. Where a dose appears it is a record of what a trial or clinic ran, or what people describe doing, with its source attached. Nothing here is a recommendation for personal use.
Part of glp-1 and metabolic peptides. Semaglutide, tirzepatide, retatrutide, and the rest of the incretin and glucagon receptor family.